| Stage | ENSG | % of rev | MEDP | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $1.5B | 100.00% | $716M | 100.00% | ENSG ×2.07 |
| Gross profit | $317M | 21.37% | $716M | 100.00% | MEDP +78.6pp |
| Operating income | $138M | 9.30% | $166M | 23.12% | MEDP +13.8pp |
| Pre-tax income | $140M | 9.45% | $171M | 23.87% | MEDP +14.4pp |
| Net income | $104M | 7.03% | $137M | 19.20% | MEDP +12.2pp |
| Stage | ENSG | MEDP | Gap · A − B |
|---|---|---|---|
| Revenue | $1.5B100.00% | $716M100.00% | ENSG ×2.07 |
| Gross profit | 21.37%$317M | 100.00%$716M | MEDP +78.6pp |
| Operating income | 9.30%$138M | 23.12%$166M | MEDP +13.8pp |
| Pre-tax income | 9.45%$140M | 23.87%$171M | MEDP +14.4pp |
| Net income |
| 7.03%$104M |
| 19.20%$137M |
| MEDP +12.2pp |